Cargando…
“Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
A central question in the assessment of benefit/harm of new treatments is: how does the average outcome on the new treatment (the factual) compare to the average outcome had patients received no treatment or a different treatment known to be effective (the counterfactual)? Randomized controlled tria...
Autores principales: | Eichler, H‐G, Bloechl‐Daum, B, Bauer, P, Bretz, F, Brown, J, Hampson, LV, Honig, P, Krams, M, Leufkens, H, Lim, R, Lumpkin, MM, Murphy, MJ, Pignatti, F, Posch, M, Schneeweiss, S, Trusheim, M, Koenig, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114686/ https://www.ncbi.nlm.nih.gov/pubmed/27650716 http://dx.doi.org/10.1002/cpt.515 |
Ejemplares similares
-
From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
por: Eichler, H‐G, et al.
Publicado: (2015) -
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need
por: Hirsch, G, et al.
Publicado: (2016) -
Causal conditionals and counterfactuals
por: Frosch, Caren A., et al.
Publicado: (2012) -
A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials
por: Selker, H P, et al.
Publicado: (2014) -
Counterfactual Desirability
por: Bradley, Richard, et al.
Publicado: (2017)